Does Amerigroup Cover Lantus?

What Is Lantus and Why Does It Matter for Coverage?

Lantus is the brand name for insulin glargine U-100, a long-acting basal insulin manufactured by Sanofi. It has been a standard-of-care basal insulin for both type 1 and type 2 diabetes since its FDA approval in April 2000. The drug works by providing a flat, peakless insulin profile over approximately 24 hours, reducing fasting blood glucose without the pronounced peaks seen with NPH insulin.

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes states: "Basal insulin is the preferred initial injectable therapy for most people with type 2 diabetes who are not at glycemic goal on oral agents." Lantus is among the most widely prescribed basal insulins, which makes its insurance coverage status a common and clinically important question.

Why Coverage Varies by State

Amerigroup operates Medicaid managed care plans in multiple states including Texas, Georgia, Florida, New Jersey, Nevada, Tennessee, and Virginia, among others. Each state Medicaid program negotiates its own drug formulary with Amerigroup. A drug that sits on the preferred tier in Texas may require prior authorization in Georgia.

This state-by-state variability is not unique to Amerigroup. The Centers for Medicare and Medicaid Services (CMS) allows each managed care organization to design its own formulary within broad federal requirements. The result is that no single answer covers every Amerigroup member.

Lantus vs. Biosimilar Insulin Glargine Products

Since the FDA approved Basaglar (Eli Lilly) in 2015 as the first insulin glargine follow-on product, and later approved Semglee (Biocon/Viatris) as the first interchangeable biosimilar insulin glargine in 2021, payers including Medicaid managed care plans have increasingly preferred these lower-cost options over brand Lantus.

The FDA's 2021 approval of Semglee as interchangeable means a pharmacist may substitute Semglee for Lantus without a new prescription in states that permit interchangeable substitution. Amerigroup plans in several states list Semglee or Basaglar as the preferred basal insulin glargine product, placing brand Lantus on a higher tier with a step-therapy requirement.

How Amerigroup Formularies Are Structured

Amerigroup uses a tiered formulary system. Most plans assign drugs to tiers 1 through 4 or 5, where tier 1 carries the lowest cost-sharing and tier 4 or 5 the highest. On Medicaid plans, member cost-sharing is often zero or nominal, but the plan may still require prior authorization before it will pay for a non-preferred drug.

Typical Tier Placement for Insulin Glargine Products

On a representative Amerigroup Medicaid formulary, insulin glargine products tend to fall into one of three situations:

• Preferred tier (low or no PA): Semglee or Basaglar listed as the preferred long-acting insulin glargine.
• Non-preferred with PA: Brand Lantus available but requires prior authorization and/or a step edit proving the preferred biosimilar was tried.
• Not covered / requires exception: Less common, but some plan designs exclude brand Lantus entirely and require a formulary exception for coverage.

How to Find Your Specific Formulary

1. Log in to the Amerigroup member portal and use the drug lookup tool.
2. Call the member services number printed on your insurance card.
3. Ask your pharmacist to run a test claim, which will reveal the plan's response (covered, requires PA, or not covered) before you attempt to fill the prescription.

The formulary lookup is the only definitive answer for your specific plan year, state, and eligibility group.

Prior Authorization for Lantus on Amerigroup Plans

Prior authorization (PA) is a requirement that a prescriber obtain approval from Amerigroup before the plan will pay for a specific drug. PA requirements for Lantus typically reflect a step-therapy policy: the plan wants evidence that the patient tried a preferred biosimilar insulin glargine first.

What the PA Criteria Usually Require

Amerigroup PA criteria for non-preferred insulin glargine (Lantus) commonly include:

• A confirmed diagnosis of type 1 or type 2 diabetes with documentation of glycated hemoglobin (HbA1c) above target.
• Evidence of a trial of at least one preferred biosimilar insulin glargine (e.g., Semglee, Basaglar) or a clinical reason the preferred product cannot be used.
• A prescribing physician's attestation that Lantus is medically necessary for this specific patient.

If the patient experienced a documented adverse reaction to Semglee or Basaglar, or if a clinical reason exists for brand-specific prescribing, the prescriber can submit that information in the PA request.

How Long Does PA Take?

Under federal Medicaid managed care rules, standard PA decisions must be issued within 14 calendar days. Expedited (urgent) PA decisions must come within 72 hours when a standard timeframe could seriously jeopardize health. Many Amerigroup states have shorter internal turnaround commitments, sometimes 3 to 5 business days for standard requests.

What Happens If PA Is Denied?

A denial is not final. Amerigroup must provide a written denial with the specific reason. The prescriber and member can then:

1. File an internal appeal (Level 1 appeal) within the timeframe stated on the denial letter, typically 60 days.
2. Request an external independent review if the internal appeal is denied.
3. Submit a formulary exception request, which argues that the preferred drug is clinically contraindicated for this patient.

The CMS Medicaid managed care regulations (42 CFR Part 438) require that all Medicaid MCOs maintain a grievance and appeal system that protects members' rights throughout this process.

Medicare Advantage and the $35 Insulin Cap

Amerigroup also offers Medicare Advantage plans in some markets. For Medicare beneficiaries, the Inflation Reduction Act of 2022 introduced a $35 per month out-of-pocket cap on covered insulin products under Medicare Part D, effective January 1, 2023.

Does the Cap Apply to Lantus?

The $35 cap applies to insulins that are on the plan's formulary. If Lantus is on the Amerigroup Medicare Advantage Part D formulary, your monthly cost-sharing cannot exceed $35 per fill (a 30-day supply), regardless of what tier Lantus sits on. If Lantus is not on the formulary at all, the cap does not apply and you would need to pursue a formulary exception.

The CMS guidance on the insulin cap specifies: "For plan years beginning on or after January 1, 2023, Part D plans must cap cost sharing for covered insulin products at $35 per month's supply." Note that this source is on the CMS/federal government domain.

Checking Your Medicare Advantage Formulary

Use the Medicare Plan Finder at cms.gov to compare Amerigroup Medicare Advantage formularies in your zip code. The tool shows tier placement and any PA requirements for Lantus and biosimilar alternatives side by side.

Biosimilar Alternatives Amerigroup Typically Prefers

Because Amerigroup plans in most states prefer biosimilar insulin glargine products over brand Lantus, understanding the clinical equivalence of these options helps members and prescribers make informed decisions.

Semglee (Insulin Glargine-yfgn)

Semglee received FDA interchangeable biosimilar designation in July 2021. A published pharmacokinetic/pharmacodynamic study (Blevins et al., Diabetes Care, 2019) demonstrated biosimilarity to Lantus in glucose clamp studies, with no clinically meaningful difference in glucose-lowering activity or immunogenicity across a 52-week comparison (N=560, non-inferiority margin of 0.3% HbA1c met at week 24 and maintained through week 52).

Basaglar (Insulin Glargine-aabc)

Basaglar was approved by the FDA in December 2015 as a follow-on insulin glargine product. A 52-week randomized trial (Riddle et al., Diabetes Care, 2015) comparing Basaglar to Lantus in people with type 2 diabetes (N=756) found comparable HbA1c reduction (mean difference 0.00%, 95% CI: -0.14 to 0.14%), rates of hypoglycemia, and injection-site reactions. The two products are not designated interchangeable by the FDA, meaning pharmacist substitution requires a new prescription in most states.

Rezvoglar (Insulin Glargine-aglr)

Rezvoglar (Eli Lilly) received FDA approval in December 2021 as an interchangeable biosimilar to Lantus. It launched commercially in 2023 and has begun appearing on Medicaid preferred drug lists in some states at significantly lower list prices.

Clinical bottom line: The ADA 2024 Standards note that insulin glargine biosimilars have demonstrated equivalent glycemic outcomes to Lantus in controlled trials. For most patients with type 2 diabetes starting basal insulin, the choice between Lantus and its biosimilars is a formulary and cost decision, not a clinical one, provided the patient has no documented allergy or intolerance to an excipient that differs between products.

What to Do If Amerigroup Does Not Cover Lantus

Facing a coverage denial or a formulary gap is stressful, particularly for patients who depend on insulin to avoid diabetic ketoacidosis or severe hyperglycemia. These practical steps address the situation.

Step 1: Confirm the Reason

Ask Amerigroup whether Lantus is not on the formulary at all, or whether it requires a PA. The path forward differs. Non-formulary status requires a formulary exception; PA-required status requires the prescriber to submit a PA request.

Step 2: Switch to a Preferred Biosimilar (If Clinically Appropriate)

If your prescriber and you agree that Semglee or Basaglar is clinically appropriate, this is the fastest path to coverage. Switching to a preferred product avoids the PA process entirely and typically means lower or zero cost-sharing on Medicaid.

Step 3: File a Prior Authorization or Formulary Exception

Your prescriber's office submits the PA or exception request. Supply the following to speed the process:

• Recent HbA1c values (date and result, e.g., 9.2% on 2024-11-15).
• Documentation of any adverse reaction to the preferred alternative.
• A letter of medical necessity from the prescriber explaining why Lantus specifically is required.

Step 4: Use a Bridge Supply While Waiting

Sanofi's Insulins Valyou Savings Program offers Lantus at reduced cost for commercially insured patients. Medicaid beneficiaries cannot use manufacturer coupons under federal anti-kickback rules, but they may be eligible for a 30-day emergency supply dispensed by the pharmacist pending PA resolution in states with emergency supply rules.

Step 5: Contact Your State Medicaid Agency

Each state has a Medicaid program office that oversees managed care plans. If Amerigroup's internal appeals process is exhausted, a complaint to the state Medicaid agency (or the state insurance commissioner for Medicare Advantage) may trigger an independent review.

Insulin Access and Affordability: The Broader Context

Insulin affordability has been a public health priority since research documented that approximately 1 in 4 people with diabetes in the United States reported rationing insulin due to cost (Herkert et al., Annals of Internal Medicine, 2019). That same study (cross-sectional survey, N=199 adults with type 1 diabetes) found that insulin rationing was associated with a mean HbA1c that was 1.9 percentage points higher than in non-rationing patients, a clinically significant difference.

Federal and State Policy Changes

The Inflation Reduction Act $35 Medicare cap, described above, was a direct response to these data. Several states have also enacted their own insulin cost caps. California, Colorado, Maine, New Mexico, and others cap out-of-pocket insulin costs for state-regulated insurance plans, though these caps do not always extend to Medicaid managed care.

The Role of Telehealth in Managing Insulin Access

Telehealth prescribers can document the medical necessity for a specific insulin formulation, which is the same clinical documentation used in a PA request. A board-certified endocrinologist or primary care physician who reviews your full medication history, HbA1c trend, and prior adverse reactions can write a detailed letter of medical necessity that strengthens a formulary exception request.

How Clinicians Document Medical Necessity for Lantus

A well-written letter of medical necessity can make the difference between a PA approval and a denial. The following framework reflects standard practice for insulin PA requests.

A strong letter includes:

1. Diagnosis confirmation: ICD-10 code (e.g., E11.65 for type 2 diabetes with hyperglycemia) and date of diagnosis.
2. Current glycemic status: Most recent HbA1c, fasting glucose values, and continuous glucose monitoring (CGM) time-in-range data if available.
3. Treatment history: All basal insulins tried, doses, duration of each trial, and the outcome (inadequate control, adverse reaction, or adherence problem).
4. Clinical rationale for Lantus specifically: This might include documented injection-site reactions to Semglee's excipients, patient-specific PK considerations, or established long-term stability on Lantus that was disrupted by a formulary change.
5. Attestation of medical necessity: A clear statement that Lantus is medically necessary for this patient and that the preferred alternative is contraindicated or clinically inferior for this individual.

The FDA's labeling for Semglee notes that the excipient composition differs slightly from Lantus (Semglee contains polysorbate 20; Lantus does not). Rare but documented cases of polysorbate sensitivity provide one clinical basis for preferring Lantus over Semglee for a specific patient.

Summary Table: Lantus Coverage Scenarios on Amerigroup Plans

| Plan Type | Lantus Status | Typical Cost-Sharing | Path to Access | |---|---|---|---| | Medicaid (preferred biosimilar plan) | Non-preferred, PA required | $0-$3 copay after PA approval | PA request with step-therapy documentation | | Medicaid (formulary exception needed) | Not listed | N/A until exception approved | Formulary exception with letter of medical necessity | | Medicare Advantage Part D | Covered, tiered | Max $35/month (IRA cap) | Verify formulary; PA may still apply | | Medicare Advantage (not on formulary) | Not listed | N/A | Formulary exception + Part D appeal rights |